evenfolio

Healthcare · NSE: METROPOLIS

Metropolis Healthcare

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
574.15+1.76%

Q2 FY27 earnings call · Guided by management

Call held 4 Nov 2026 · Read the filing on NSEFiling

16​%Revenue growth · FY27Chemmenkotil · Q&A · p. 17
₹65–70​CrAnnual capex · FY27Chemmenkotil · Q&A · p. 16
180–200​bpsEBITDA margin expansion · FY27Chemmenkotil · Q&A · p. 17
180–190​bpsEBITDA margin expansion · FY27Chemmenkotil · Q&A · p. 15
M.Cap
₹11,907Cr
P/E
53.1×
1Y return
+16.53%
From 52W high
−5.7%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue497429+15.8%450+10.4%
EBITDA134108+23.8%111+20.5%
EBITDA margin27.0%25.2%+176 bps24.7%+228 bps
PBTProfit before tax10271+44.3%78+31.9%
Net profit7553+43.0%57+32.9%
EPS (₹)3.6010.13-64.5%2.73+31.9%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Revenue growth · FY2716%FY27 revenue growth of about 16% and 180-200 bps margin gain expected to continue for rest of year
EBITDA margin · FY27180-200 bpsEBITDA margin expansion of about 180 to 200 bps expected to continue for FY27
EBITDA margin · long term125-150 bpsMargin improvement of maybe 125 to 150 bps seen in coming years, net of new investments
Capex · FY27Rs 65-70 CrCapex of about Rs 65 to 70 crore expected this year, same range as before

Similar growth and margin trajectory expected for rest of the year

Ameera Shah · Chairperson and Whole · p. 3
“As we move forward, we are optimistic of continuing similar growth and margin trajectory for the rest of the year.”

More figures from the call

Company · Guidance
30–35​centers per labCenter-to-lab ratio · next 2 years
“Network density is increasing as we add centers around existing labs, taking our center-to-lab ratio from 24:1 towards 30:1 and then 35:1 over the next 2 years.”
Surendran Chemmenkotil · Managing Directorp. 9
Company · Guidance
30​centers per labCenter-to-lab ratio · FY27
“And we said that we will take this up to maybe close to 30 by the end of this year and then maybe end of next year to a 30:1 to 35:1 ratio.”
Surendran Chemmenkotil · Managing Directorp. 11
Company · Capex
4–5​%Capex range (overall) · FY27
“So we did mention in the past that our capex will be in the range of 4% to 5% overall, right?”
Surendran Chemmenkotil · Managing Director · Q&Ap. 16
Company · Capacity
750​townsTowns of operation
“See, one is we have stopped adding any more new labs, and we stay put with 750 towns for operations, right?”
Surendran Chemmenkotil · Managing Directorp. 11
Company · Capacity
116​centersCollection centers added · Q2 FY27
“During the quarter, we added 116 collection centers, taking our net additions to 700 over the last 24 months.”
Surendran Chemmenkotil · Managing Directorp. 8
Company · Margins and costs
125–170​bpsEBITDA margin expansion guidance · Q2 FY27
“well ahead of our guidance of 125 to 170 basis points. This improvement came from volume-led operating leverage, disciplined cost management and steady progress on our productivity agenda.”
Surendran Chemmenkotil · Managing Directorp. 9

In short

  1. 01Management expects H1 trends of about 16% revenue growth and 180 to 200 bps margin gain to continue for the rest of FY27.
  2. 02Q2 FY27 revenue was Rs 497 crore, up 16%; EBITDA margin rose 180 bps to 27.2%; PAT was Rs 75 crore, up 43%.
  3. 03A price increase for part of the business, B2C for now, is planned for Q4 or early next year.
  4. 04Management sees room to improve margins by 125 to 150 bps in the coming years.
  5. 05Capex is expected at about Rs 65 to 70 crore this year; no new labs are being added.
  6. 06Specialty and TruHealth each grew 20%; Tier 3 and rural centers grew about 20%.
  7. 07IRR on the Core Diagnostics acquisition is estimated at about 13%; Core reached double-digit margin last quarter.
  8. 08An interim dividend of Rs 1 per share was declared.

Segments

B2C: Existing centers delivered same-store growth of 10%

Surendran Chemmenkotil · Managing Director · p. 8
“Growth was broad-based across both mature and newer centers with existing centers delivering same-store growth of 10% and improved retail productivity, while newer centers continue to ramp up.”

B2B: B2B business grew 15%

Surendran Chemmenkotil · Managing Director · p. 8
“Our B2B business grew 15%, reflecting our focused approach of partnering with hospitals, clinicians and quality-led institutions where our science expertise and specialty portfolio give us a clear edge.”

B2B: B2B patient volume up 7%, test volume up 11%

Surendran Chemmenkotil · Managing Director · p. 8
“Within B2B, patient volume grew by 7% and test volume grew by 11% which means partners are sending us more tests per patient, a clear sign of growing wallet share.”

B2B: B2B partner network crossed 9,000 partners

Surendran Chemmenkotil · Managing Director · p. 8
“We continue to add new lab and hospital partnership during the quarter, and B2B partner network has now crossed 9,000 partners.”

TruHealth and Specialty: TruHealth 17% of revenue, Specialty 40%; both grew 20% in Q2

Sameer Patel · Chief Financial Officer · p. 10
“TruHealth contributed 17% of revenue and grew 20% on a year-on-year basis, while Specialty contributed 40% of revenue and grew 20% on a year-on-year basis.”

Demand

Patient volumes grew 10%, test volume around 11%

Surendran Chemmenkotil · Managing Director · p. 7
“Patient volumes grew by 10% and test volume around 11% with the balance coming from a richer test mix and better realization.”

Unclear if hospital price pressure leads to more test outsourcing

Ameera Shah · Chairperson and Whole · Q&A · p. 19
“Now whether that results in more outsourcing of tests, I think we'll have to wait and watch.”

Tier 2, Tier 3 towns: New centers and labs in Tier 2 and Tier 3 towns becoming productive

Surendran Chemmenkotil · Managing Director · Q&A · p. 19
“One is all the new centers and the labs that we put up over the last, let's say, a couple of years in the Tier 2, Tier 3 towns are all becoming productive.”

Smaller unorganised players seen shutting down as quality and specialty testing grow

Ameera Shah · Chairperson and Whole · Q&A · p. 13
“And we've been seeing that happening over the last few years, even without government regulation that as quality comes to the fore, as consumers become more conscious, as specialized testing increases, which the unorganized guys can't do, we have seen smaller players shut down and not be able to operate in the market.”

B2B hospitals: More hospital outsourcing of tests they already run in-house seen as unlikely

Surendran Chemmenkotil · Managing Director · Q&A · p. 18
“But whether there's an opportunity for them not to do some of the tests and I mean outsource to us, I mean, that's unlikely because they already have the lab and arrangements there.”

Margins and costs

H1 EBITDA margin up 190 bps to 26.2%, without any price increase

Ameera Shah · Chairperson and Whole · p. 3
“Importantly, we have delivered the step-up in growth while expanding EBITDA margins by 190 basis points to 26.2% EBITDA margin for the first half, and this is without any price increase so far in the year.”

Q2 EBITDA Rs 135 crore, up 24% year-on-year

Sameer Patel · Chief Financial Officer · p. 10
“With respect to quarter 2 margin, EBITDA stood at INR135 crores, growing 24% year-on-year.”

Q2 EBITDA margin up 180 bps to 27.2%; PAT Rs 75 crore, up 43%

Sameer Patel · Chief Financial Officer · p. 10
“EBITDA margin expanded 180 basis points to 27.2%. PAT stood at INR75 crores, growing at 43% year-on-year.”

Q2 PAT margin up 290 bps to 15.2%, highest post-COVID

Sameer Patel · Chief Financial Officer · p. 10
“PAT margin expanded 290 basis points to 15.2%.”

Last price increase in January 2025; next price revision being evaluated for early next year

Surendran Chemmenkotil · Managing Director · p. 9
“Lastly, on the pricing front, our last price increase was implemented in January '25, and we are currently evaluating the possibility of the next price revision maybe early next year.”

Debt and working capital

Net working capital days at 13, down from 16 in FY26

Sameer Patel · Chief Financial Officer · p. 10
“our net working capital days stood at 13 days compared to 16 days in FY26.”

Cash and liquid investments Rs 348 crore at 30 Sep 2026, up from Rs 203 crore in March

Sameer Patel · Chief Financial Officer · p. 10
“Our cash and liquid investments stood at INR348 crores as on 30th September 2026 compared to INR203 crores as on 31st March 2026, building a strong cash position to fund further our organic and inorganic growth.”

Acquisitions and new business

Specialty: 43 specialty and super specialty tests added in H1

Surendran Chemmenkotil · Managing Director · p. 8
“We added 43 specialty and super specialty tests in the first half of the year, giving us further headroom for growth.”

Core Diagnostics: IRR on Core acquisition estimated at about 13% in past year, to accelerate in H2

Ameera Shah · Chairperson and Whole · p. 6
“Taking into account the acceleration of our genomics business, we estimate that in the past year, our IRR on the Core acquisition is at about 13%, and this will only accelerate in H2 as revenue growth increases and margins expand.”

Core Diagnostics: Core Diagnostics had double-digit margin last quarter

Surendran Chemmenkotil · Managing Director · Q&A · p. 17
“So we had a double-digit margin in the last quarter for Core Diagnostics.”

Core Diagnostics: Core was at breakeven at acquisition 1.5 years ago, now near double-digit margins

Ameera Shah · Chairperson and Whole · p. 6
“On margins, Core was at breakeven when we acquired it 1.5 years ago, and today, it is delivering near double-digit margins.”

DAPIC, Scientific: DAPIC and Scientific growing in line with company, margins above company level

Ameera Shah · Chairperson and Whole · p. 6
“DAPIC in Dehradun and Scientific in Agra are both growing in line with the company average, while delivering margins higher than the overall company margins, which validates both our selection and our integration approach.”

Dividends and buybacks

Interim dividend of Rs 1 per share declared

Ameera Shah · Chairperson and Whole · p. 7
“But before that, I just want to announce that the company has declared an interim dividend of INR1 per share.”

Management

Core Diagnostics: Planned restructuring of Core team completed

Ameera Shah · Chairperson and Whole · p. 6
“We have also completed a planned restructuring of the Core team.”

Risks

Q2 monsoon among weakest in 2 decades, rainfall about 13% below normal

Ameera Shah · Chairperson and Whole · p. 3
“It's also worth noting that we delivered this growth in a quarter where the monsoon was one of the weakest in over 2 decades, with rainfall about 13% below normal and highly uneven across regions.”

Hospital drug price caps have no bearing on the business

Ameera Shah · Chairperson and Whole · p. 4
“Let me be clear that this has no bearing on our business, either financially or operationally.”

No move towards price capping or price parity in diagnostics

Ameera Shah · Chairperson and Whole · p. 4
“They do not extend to diagnostics, and there is no move towards price capping or price parity in our segment.”

Other

H1 FY27 revenue grew 16.2%, ahead of stated guidance

Ameera Shah · Chairperson and Whole · p. 3
“However, over the last 4 to 6 quarters, we have stepped that up to 15% to 16% with revenue growing at 16.2% for H1 FY27, ahead of our stated guidance.”

Q2 FY27 revenue Rs 497 crore, up 16%; patient volumes up 10%, test volumes up 11%

Sameer Patel · Chief Financial Officer · p. 10
“Quarter 2 FY27 revenue stood at INR497 crores with a growth of 16% year-on-year, supported by 10% growth in patient volumes and 11% growth in test volumes.”

CGHS revenue contribution minimal; growth purely volume and mix based

Surendran Chemmenkotil · Managing Director · p. 7
“Our revenue contribution from CGHS is minimal, so our growth has been purely volume and mix based.”

Evolving regulation, including NMC remote report authorisation, seen as a tailwind

Ameera Shah · Chairperson and Whole · p. 5
“Taken together, we see the evolving regulatory landscape as a clear tailwind.”

H2 rollout of new CRM, dynamic pricing engine, sales app and SLIMS integration

Surendran Chemmenkotil · Managing Director · p. 9
“We will be rolling out a new CRM platform, a dynamic pricing engine and new sales app for our field teams and an enhanced SLIMS integration capabilities across our laboratories.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools